MY181915A - Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases - Google Patents

Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases

Info

Publication number
MY181915A
MY181915A MYPI2015703843A MYPI2015703843A MY181915A MY 181915 A MY181915 A MY 181915A MY PI2015703843 A MYPI2015703843 A MY PI2015703843A MY PI2015703843 A MYPI2015703843 A MY PI2015703843A MY 181915 A MY181915 A MY 181915A
Authority
MY
Malaysia
Prior art keywords
igf
antibodies
treatment
fcrn
eye diseases
Prior art date
Application number
MYPI2015703843A
Inventor
Hartmann Guido
Thomas Regula Joerg
Rueth Matthias
Schaefer Wolfgang
Schlothauer Tilman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2014/058418 external-priority patent/WO2014177461A1/en
Publication of MY181915A publication Critical patent/MY181915A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

The invention provides anti-IGF-lR antibodies with abolished FcRn-binding and methods of using the same for the treatment of vascular eye diseases.
MYPI2015703843A 2013-04-29 2014-04-25 Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases MY181915A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13165741 2013-04-29
PCT/EP2014/058418 WO2014177461A1 (en) 2013-04-29 2014-04-25 Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases

Publications (1)

Publication Number Publication Date
MY181915A true MY181915A (en) 2021-01-14

Family

ID=48190315

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2015703843A MY181915A (en) 2013-04-29 2014-04-25 Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases

Country Status (3)

Country Link
AR (1) AR096092A1 (en)
MA (1) MA38561B1 (en)
MY (1) MY181915A (en)

Also Published As

Publication number Publication date
MA38561A1 (en) 2017-09-29
AR096092A1 (en) 2015-12-02
MA38561B1 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
PH12020550781A1 (en) Anti-jagged1 antibodies and methods of use
MX2019005299A (en) Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases.
PH12016501618A1 (en) Anti-dll3 antibodies and drug conjugates for use in melanoma
PH12016501894A1 (en) Anti-ox40 antibodies and methods of use
PH12017500877A1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2017000116A (en) Il-15-based molecules and methods of use thereof.
PH12016501644A1 (en) Binding proteins and methods of use thereof
NZ731467A (en) Anti-tim3 antibodies and methods of use
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
MX2015012326A (en) Anti-crth2 antibodies and their use.
SG10201804338PA (en) Anti-fcrh5 antibodies
IL251128A0 (en) Bispecific antibodies and methods of use in ophthalmology
MX2017007491A (en) Blood brain barrier receptor antibodies and methods of use.
MX2017005975A (en) Anti-pdgf-b antibodies and methods of use.
MX2015014713A (en) Use of a composition comprising fish oil and juice for the treatment and/or post treatment of cancer.
MX2016003293A (en) Methods and compositions for treatment of chlamydial infection and related diseases and disorders.
MX2016015280A (en) Anti-brdu antibodies and methods of use.
MX2019014090A (en) Methods for the treatment of chronic pouchitis.
MY181915A (en) Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
UA115417U (en) METHOD OF PREVENTION AND TREATMENT OF HYPOXIC CHANGES IN CARBOPERITONEUM
TH1501006544A (en) Anti-IGF-1R antibody which abolishes the -FcRn bond and its use. in the treatment of eye vascular disease